Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy

Biomaterials

Volumn 76, Issue , 2016, Pages 238-249

  Xu, Xiao Ding ^a,b   Cheng, Yin Jia ^a   Wu, Jun ^b   Cheng, Hong ^a   Cheng, Si Xue ^a   Zhuo, Ren Xi ^a   Zhang, Xian Zheng ^a  

^a WUHAN UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Assembly; Cancer therapy; Hyper fast drug release; Polyprodrug; Redox responsive

Indexed keywords

ASSEMBLY; CARDIOVASCULAR SYSTEM; CHAINS; ETHYLENE; HYDROPHILICITY; ONCOLOGY; POLYETHYLENE OXIDES; TUMORS;

10 HYDROXYCAMPTOTHECIN (HCPT); BIODEGRADABLE NANOPARTICLE; CANCER THERAPY; DRUG RELEASE; INHIBITION OF TUMOR GROWTH; POLYPRODRUG; REDOX-RESPONSIVE; TARGETED CANCER THERAPY;

DISEASES;

10 HYDROXYCAMPTOTHECIN; MACROGOL; POLYMER; POLYMERIC PRODRUG; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONFOCAL LASER SCANNING MICROSCOPE; CONJUGATE; CONTROLLED STUDY; COS 7 CELL LINE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; NEOPLASMS; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CERCOPITHECUS AETHIOPS; COS CELLS; HEP G2 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS;

EID: 84961199094     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.056     Document Type: Article

References (50)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-7602.
2. Farokhzad O.C., Margalit R., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
3. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63:185-198.
4. Leong K.W., Sung H.W. Nanoparticle- and biomaterials-mediated oral delivery for drug, gene, and immunotherapy. Adv. Drug Deliv. Rev. 2013, 65:757-758.
5. Mo R., Jiang T., Di J., Tai W., Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem. Soc. Rev. 2014, 43:3595-3629.
6. Albert A. Chemical aspects of selective toxicity. Nature 1958, 182:421-422.
7. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46:69-185.
8. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
9. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
10. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 2008, 60:886-898.
11. MacKay J.A., Chen M.N., McDaniel J.R., Liu W., Simnick A.J., Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 2009, 8:993-999.
12. Mahato R., Tai W., Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv. Drug Deliv. Rev. 2011, 63:659-670.
13. Yang J., Liu W., Sui M., Tang J., Shen Y. Prodrugs for improving tumor targetability and efficiency. Biomaterials 2011, 32:9136-9143.
14. Homsi J., Simon G.R., Garrett C.R., Springett G., De Conti R., Chiappori A.A., et al. Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 2007, 13:5855-5861.
15. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., et al. Phase II studies of polymer-doxorubicin (PK1, RCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
16. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Payner R., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
17. Dharap S.S., Wang Y., Chandna P., Khandare J.J., Qiu B., Gunaseelan S., et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12962-12967.
18. Quan C.Y., Chen J.X., Wang H.Y., Li C., Chang C., Zhang X.Z., et al. Core-shell nanosized assemblies mediated by the α-β cyclodextrin dimer with a tumor-triggered targeting property. ACS Nano 2010, 4:4211-4219.
19. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 2011, 133:17560-17563.
20. Zhang J., Xu X.D., Liu Y., Liu C.W., Chen X.H., Li C., et al. Design of an "active defense" system as drug carriers for cancer therapy. Adv. Funct. Mater. 2012, 22:1704-1710.
21. Du J.Z., Sun T.M., Song W.J., Wu J., Wang J. A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew. Chem. Int. Ed. 2010, 49:3621-3626.
22. Ryu J.H., Chacko R.T., Jiwpanich S., Bickerton S., Babu R.P., Thayumanavan S. Self-cross-linked polymer nanogels: a versatile nanoscopic drug delivery platform. J. Am. Chem. Soc. 2010, 132:17227-17235.
23. Cao W., Zhang X., Miao X., Yang Z., Xu H. γ-Ray-responsive supramolecular hydrogel based on a diselenide-containing polymer and a peptide. Angew. Chem. Int. Ed. 2013, 52:6233-6237.
24. Li Y.L., Zhu L., Liu Z., Cheng R., Meng F., Cui J.H., et al. Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells. Angew. Chem. Int. Ed. 2009, 48:9914-9918.
25. Thornton P.D., Mart R.J., Ulijn R.V. Enzyme-responsive polymer hydrogel particles for controlled release. Adv. Mater. 2007, 19:1252-1256.
26. Li J., Gao Y., Kuang Y., Shi J., Du X., Zhou J., et al. Dephosphorylation of d-peptide derivatives to form biofunctional, supramolecular nanofibers/hydrogels and their potential applications for intracellular imaging and intratumoral chemotherapy. J. Am. Chem. Soc. 2013, 135:9907-9914.
27. Ghadiali J.E., Stevens M.M. Enzyme-responsive nanoparticle systems. Adv. Mater. 2008, 20:4359-4363.
28. Zhang Y., Yin Q., Yin L., Ma L., Tang L., Cheng J. Chain-shattering polymeric therapeutics with on-demand drug-release capability. Angew. Chem. Int. Ed. 2013, 52:6435-6439.
29. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2013, 66C:2-25.
30. Giancotti F.G., Ruoslahti E. Integrin signaling. Science 1999, 285:1028-1032.
31. Xu X.D., Cheng H., Chen W.H., Cheng S.X., Zhuo R.X., Zhang X.Z. In situ recognition of cell-surface glycans and targeted imaging of cancer cells. Sci. Rep. 2013, 3:2679.
32. Pearce T.R., ShroffK., Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv. Mater. 2012, 24:3803-3822.
33. Meng F., Hennink W.E., Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009, 30:2180-2198.
34. Cheng R., Feng F., Meng F., Deng C., Feijen J., Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control Release 2011, 152:2-12.
35. Lee M.H., Kim J.Y., Han J.H., Bhuniya S., Sessler J.L., Kang C., et al. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted rgd peptide-appended naphthalimide theragnostic prodrug. J. Am. Chem. Soc. 2012, 134:12668-12674.
36. Lee M.H., Han J.H., Lee J.H., Choi H.G., Kang C., Kim J.S. Mitochondrial thioredoxin-responding off-on fluorescent probe. J. Am. Chem. Soc. 2012, 134:17314-17319.
37. Hu X.L., Liu G.H., Li Y., Wang X.R., Liu S.Y. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals. J. Am. Chem. Soc. 2015, 137:362-368.
38. Luo Z., Cai K.Y., Hu Y., Zhao L., Liu P., Duan L., et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew. Chem. Int. Ed. 2011, 50:640-643.
39. Pan Y.J., Chen Y.Y., Wang D.R., Wei C., Guo J., Lu D.R., et al. Redox/pH dual stimuli-esponsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release. Biomaterials 2012, 33:6570-6579.
40. Remant B.K., Chandrashekaran V., Cheng B., Chen H., Pena M.M., Zhang J., et al. Mol. Pharm. 2014, 11:1897-1905.
41. Nemeth J.A., Nakada M.T., Trikha M., Lang Z., Gordon M.S., Jayson G.C., et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007, 25:632-646.
42. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
43. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
44. Wang Y., Zhou K., Huang G., Hensley C., Huang X., Ma X., et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 2014, 13:204-212.
45. Burke T.G., Mi Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. 1993, 36:2580-2582.
46. Huang X., Peng X., Wang Y., Wang Y., Shin D.M., El-Sayed M.A., et al. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano 2010, 4:5887-5896.
47. Hu X., Hu J., Tian J., Ge Z., Zhang G., Luo K., et al. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery. J. Am. Chem. Soc. 2013, 135:17617-17629.
48. Wall M.E., Wani M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain memorial award lecture. Cancer Res. 1995, 55:753-760.
49. Giovanella B.C., Cheng H.R. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin. Cancer Res. 1991, 51:3052-3055.
50. Bhuniya S., Maiti S., Kim E.J., Lee H., Sessler J.L., Hong K.S., et al. An activatable theranostic for targeted cancer therapy and imaging. Angew. Chem. Int. Ed. 2014, 53:4469-4474.